Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a growth company: Discounted cash flow and EV/EBITDA comparison.
ACCE opinionXeris Biopharma Holdings Inc. Common Stock (XERS)
Fair value (2 models)
Not available
ACCE price target
$10.50
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $10.20 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
51
out of 100
Analysts
86% buy
7 covering
1-year return
+11.7%
Dividend yield
0.00%
Xeris Biopharma Holdings Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Xeris Biopharma sells Gvoke, a ready-to-use liquid glucagon pen for severe hypoglycemia, along with Xeris's own Gvoke PFS and its XeriSol-based formulations, and it has been moving from a loss-making launch toward operating profitability. Its edge is in the product itself: the room-temperature, no-mixing formulation is easier for patients and caregivers to use in an emergency than the powder kits it competes with, and gross margins of 86.6% reflect a branded specialty product rather than a generic. Revenue growth of 28.7% and a positive 5.6% operating margin show the commercial build-out is starting to pay off, though the 36.9x forward P/E is pricing in more of that improvement than the trailing numbers support. The stock is interesting now because the profit inflection is recent and the next few quarters will show whether Gvoke's volume growth can keep operating leverage moving; the negative -617.2% ROE, reflecting past losses and a thin equity base, is the main reason to look closely before going further.